New York Times CENTER-LEFT (-1.0) Reliability: 8.0/10

Drug With a 30-Year Monopoly Is Target of State-Level Push to Curb Prices

✍️ Rebecca Robbins 📅 October 23, 2025 12:00 AM 🕐 Scraped: October 23, 2025

Summary: In a first, Colorado will cap the price of Enbrel, an arthritis drug. Using patent tactics, the drugmaker Amgen has aggressively blocked competition for it.

Starting in January, Medicare will demand a lower, negotiated price of about $30,000 a year for the drug.

📰

Continue Reading on New York Times

This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.

Read Full Article →

How do you feel about this article?

Read Original Article →

📝 Article Information

Author

Rebecca Robbins

Original Publisher

🌍 New York Times

CENTER-LEFT Bias (-1.0)

Published Date

October 23, 2025 at 12:00 AM

ℹ️

Disclaimer

ArkforgeAI.com - Newsource is a news aggregation platform. We do not create, write, or produce original news content. All articles are sourced from their respective publishers and remain the property of their original creators. We analyze and aggregate news from multiple sources to provide diverse perspectives across the political spectrum.

The content displayed here is for informational purposes only. For the complete and original article, please visit the source's website using the "Read Original Article" link above.

Desktop Only